April 7, 2016
Registered in Cuba to treat head, neck, brain (in children and adults), esophageal and more recently, pancreatic tumors, with encouraging results, the humanized monoclonal antibody, nimotuzumab, is currently subject to 27 clinical trials to ensure its safety and effectiveness in the treatment of a further 11 types of cancer
Nimotuzumab is produced in the laboratories of Cuba’s Center of Molecular Immunology Photo: Jose M. Correa
Registered in Cuba to treat head, neck, brain (in children and adults), esophageal and more recently, pancreatic tumors, with encouraging life-extending results, the humanized monoclonal antibody nimotuzumab is currently subject to 27 clinical trials to ensure its safety and effectiveness in the treatment of a further 11 types of cancer.
Approved and registered for use in 24 countries
Several of these trials are taking place in Japan, South Korea, Indonesia and the Philippines. A previous 37 clinical trials took place in nations such as Canada, India, Germany, China and Brazil. To date, nimotuzumab has been approved and registered for use in 24 countries.
The medicine was created by doctors Cristina Mateo Acosta del Río, Rolando Pérez Rodríguez and Ernesto Moreno Frías, of Cuba’s Center of Molecular Immunology (CIM), part of the BioCubaFarma Enterprise Group, and is applied in combination with radiotherapy and chemotherapy.
To transform cancer
Nimotuzumab forms part of the portfolio of products developed at this scientific institution, which aim to inhibit tumor growth and even reduce tumor size, in order to transform cancer into a manageable chronic condition with an acceptable quality of life.
Precisely from this Thursday, April 7, the 9th International Scientific Meeting, Nimomeeting 2016, will be held at the Hotel Meliá Marina in Varadero, where some 150 researchers from 19 countries will discuss the clinical results of the use of this promising Cuban drug to treat various types of tumor.